Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHOTCMKTS:PXSLYNASDAQ:RTTRNASDAQ:TLGTNASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.16$0.18$0.12▼$3.39$1.33M-0.03218,748 shs10,684 shsPXSLYPharmaxis$0.88$0.88$0.62▼$1.47$26.53M1.221,000 shsN/ARTTRRitter Pharmaceuticals$3.39+7.3%$2.99$0.15▼$1.27$156.46M-0.4314.23 million shs29,637 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsVTGNVistaGen Therapeutics$2.41+9.0%$2.28$1.90▼$4.21$69.84M0.61180,276 shs109,774 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-6.03%-5.59%-15.53%+7.00%-90.61%PXSLYPharmaxis0.00%0.00%0.00%0.00%0.00%RTTRRitter Pharmaceuticals0.00%-10.99%-15.73%+0.64%+1,028.57%TLGTTeligent0.00%0.00%0.00%0.00%0.00%VTGNVistaGen Therapeutics+9.14%+10.50%-6.36%+8.87%-35.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path0.7436 of 5 stars0.05.00.00.00.00.01.3PXSLYPharmaxisN/AN/AN/AN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AVTGNVistaGen Therapeutics1.5606 of 5 stars0.05.00.00.01.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 0.00N/AN/AN/APXSLYPharmaxis 0.00N/AN/AN/ARTTRRitter Pharmaceuticals 0.00N/AN/AN/ATLGTTeligent 0.00N/AN/AN/AVTGNVistaGen Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest VTGN, TLGT, RTTR, PXSLY, and BPTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025VTGNVistaGen TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/APXSLYPharmaxis$8.75M3.03N/AN/A$0.04 per share22.00RTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/ATLGTTeligentN/AN/AN/AN/AN/AN/AVTGNVistaGen Therapeutics$490K143.30N/AN/A$2.44 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)PXSLYPharmaxis-$9.36MN/A0.00∞N/AN/AN/AN/AN/ARTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/ATLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/AVTGNVistaGen Therapeutics-$51.42M-$1.66N/AN/AN/A-6,777.08%-58.88%-52.38%8/12/2025 (Estimated)Latest VTGN, TLGT, RTTR, PXSLY, and BPTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025VTGNVistaGen Therapeutics-$0.52-$0.43+$0.09-$0.43$0.18 million($0.01) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/APXSLYPharmaxisN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86PXSLYPharmaxis2.823.312.92RTTRRitter PharmaceuticalsN/A3.673.67TLGTTeligentN/AN/AN/AVTGNVistaGen TherapeuticsN/A6.516.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%PXSLYPharmaxisN/ARTTRRitter Pharmaceuticals0.84%TLGTTeligentN/AVTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%PXSLYPharmaxisN/ARTTRRitter Pharmaceuticals15.40%TLGTTeligent0.17%VTGNVistaGen Therapeutics1.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionablePXSLYPharmaxis6930.15 millionN/ANot OptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableTLGTTeligent2,357N/AN/AOptionableVTGNVistaGen Therapeutics4029.16 million28.78 millionOptionableVTGN, TLGT, RTTR, PXSLY, and BPTH HeadlinesRecent News About These CompaniesStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comWilliam Blair Issues Negative Forecast for VTGN EarningsJune 23, 2025 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comWilliam Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)June 20, 2025 | theglobeandmail.comVistagen Therapeutics’ Earnings Call Highlights Progress and ChallengesJune 19, 2025 | tipranks.comWhat is William Blair's Forecast for VTGN Q1 Earnings?June 19, 2025 | marketbeat.comVistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William BlairJune 18, 2025 | marketbeat.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...June 18, 2025 | finance.yahoo.comVistagen Therapeutics Reports Progress in Clinical TrialsJune 17, 2025 | tipranks.comVistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comVistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSJune 17, 2025 | marketbeat.comVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | businesswire.comInsights into VistaGen Therapeutics's Upcoming EarningsJune 16, 2025 | benzinga.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look ForJune 16, 2025 | gurufocus.comVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025June 12, 2025 | businesswire.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comWhy Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%April 8, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTGN, TLGT, RTTR, PXSLY, and BPTH Company DescriptionsBio-Path NASDAQ:BPTH$0.16 0.00 (0.00%) As of 10:02 AM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Pharmaxis OTCMKTS:PXSLY$0.88 0.00 (0.00%) As of 06/8/2021Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.Ritter Pharmaceuticals NASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.Teligent NASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.VistaGen Therapeutics NASDAQ:VTGN$2.41 +0.20 (+8.96%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Why Centene Stock Dropped 40% — And Whether It's a Buy Now D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
